Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKKMarkus Borner, Walter Mingrone, Dieter Koeberle et al.|Annals of Oncology|2008Cited by 129
What are the most important unanswered research questions in trial retention? A James Lind Alliance Priority Setting Partnership: the PRioRiTy II (Prioritising Retention in Randomised Trials) studyDan Brunsdon, Katie Gillies, Doris Lanz et al.|Trials|2019Cited by 116
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicityMarkus Borner, A. Roth, J. Bernhard et al.|Annals of Oncology|2005Cited by 103
The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)Markus Borner, A. Roth, Walter Mingrone et al.|Journal of Clinical Oncology|2006Cited by 26
Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKKUte Gick, Stefan Aebi, Christoph Rochlitz et al.|Oncology|2006Cited by 10